General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-08 | 2024-03 | -0.61 | -0.73 | -0.12 | -19.67% |
2024-04-03 | 2023-12 | -0.59 | N/A | N/A | N/A |
2023-11-01 | 2023-09 | -0.63 | N/A | N/A | N/A |
2023-11-01 | 2023-09 | -0.63 | -0.61 | 0.02 | 3.17% |
2023-08-02 | 2023-06 | -0.65 | -0.63 | 0.02 | 3.08% |
2023-08-02 | 2023-06 | -0.65 | N/A | N/A | N/A |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-09-27 | Piper Sandler | Upgrade | Overweight | |
2023-08-06 | Mizuho | Upgrade | Neutral | Neutral |
2023-08-02 | Morgan Stanley | Upgrade | Overweight | Overweight |
2023-08-02 | B of A Securities | Downgrade | Buy | Neutral |
2023-08-02 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-05-22 | Goldman Sachs | Upgrade | Neutral | Neutral |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2023-12-19 | AKAMINE SCOTT | Officer | 7.24K | Sale |
2023-12-19 | ALTSCHULLER SUSAN | Chief Financial Officer | 16.91K | Sale |
2023-12-19 | BODENRADER MARK | Officer | 17.72K | Sale |
2023-12-18 | BURGESS PAUL D | Officer | 45.73K | Conversion of Exercise of derivative security |
2024-05-09 | COLES NEAVELLE ANTHONY | Director | 15.64K | Sale |
2023-12-21 | DIPIETRO KENNETH AMADEO | Officer | 24.66K | Sale |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Bain Capital Investors, LLC | 60.20M | 1.91B | 38.23% |
2023-06-29 | FMR, LLC | 23.49M | 746.87M | 14.92% |
2023-06-29 | Perceptive Advisors Llc | 10.09M | 320.71M | 6.41% |
2023-06-29 | Vanguard Group Inc | 5.66M | 180.01M | 3.60% |
2023-06-29 | Price (T.Rowe) Associates Inc | 5.22M | 166.10M | 3.32% |
2023-06-29 | Blackrock Inc. | 4.83M | 153.63M | 3.07% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-08-30 | Fidelity Growth Company Fund | 5.77M | 136.72M | 3.66% |
2023-06-29 | Price (T.Rowe) Health Sciences Fund | 1.93M | 61.32M | 1.22% |
2023-05-30 | Fidelity Growth Company K6 Fund | 1.83M | 59.64M | 1.16% |
2023-06-29 | Vanguard Total Stock Market Index Fund | 1.80M | 57.13M | 1.14% |
2023-06-29 | Price (T.Rowe) New Horizons Fund | 1.75M | 55.54M | 1.11% |
2023-08-30 | Fidelity Series Growth Company Fund | 1.70M | 40.18M | 1.08% |
So glad I quit when it was $27. Lost 23k but plenty of other opportunities $NTLA
I got out at $27 w loss of 25k. Bc price offering was made that day. And stock doing good so far. Folks create FUD & scare retail investors.
Bears are stupidity greedy! Watch this stock go over $40 in after hours! The drug they engineered works w multiple severe mental illness & has such a large spectrum of uses
Guys don’t panic sell Bc of offering! It’s great for company Bc raise more capital & higher stock potential & value despite dilution, this is a keeper!
Price will go up again ! Even tomoroiw
hehehe
Bears R the only ones calling $CERE garbage
Folks let go of ur stop losses …$Cere wants to rip 40++++ now !!!!!
$CERE worth over $500 near future …prime & only drug for Parkinson’s …buy now !!!!
Remove all stop loss
Remove all stop losses you shit heads
Buy buy buy before hits $50
Quick question for bulls only! Pls answer fast, anyone knows PT for cere? Should I sell or hold at 27? Pls tell me
Hee hoeewwwww ️️️
Sorry meant $50
Power hour about to begin…let’s kill all bears$CERE top trending stock …price to go over $150 at close
Blast to $40 coming $CERE️️️️️️